The anti-PD-1 drug pembrolizumab demonstrated promising anti-tumor activity in patients with heavily pretreated classic Hodgkin lymphoma.
Hematologic Cancer Targets
In this podcast from the 2014 American Society of Hematology Annual Meeting, we discuss some of the new developments in multiple myeloma.
The anti–PD-1 (programmed death 1) antibody nivolumab has shown activity in patients with hematologic cancers who have failed three or more prior therapies.
Adding carfilzomib to lenalidomide and dexamethasone resulted in a higher PFS and better overall quality of life for relapsed multiple myeloma patients.
T-lymphoblastic leukemia (T-ALL) should no longer be considered a poor-risk disease in the pediatric population, according to data presented at ASH.
Sorafenib proved to have a high level of efficacy in younger acute myeloid leukemia patients, improving both event- and relapse-free survival over placebo.
The FDA has approved blinatumomab (Blincyto) for the treatment of patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia.
Ahead of the 2014 ASH Annual Meeting & Exhibition we discuss current treatment strategies for elderly patients with acute myeloid leukemia.
Early trial data support further evaluation of ixazomib combined with lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Non-germinal center B-cell-like DLBCL patients derived the most benefit from treatment with the immunochemotherapy regimen R-ACVBP compared with R-CHOP.